Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Net Income (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Net Income for 4 consecutive years, with -$28.6 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 61.78% to -$28.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$183.2 million through Dec 2025, up 36.21% year-over-year, with the annual reading at -$183.2 million for FY2025, 36.21% up from the prior year.
  • Net Income hit -$28.6 million in Q4 2025 for Axsome Therapeutics, up from -$47.2 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$11.2 million in Q1 2023 to a low of -$98.7 million in Q4 2023.
  • Historically, Net Income has averaged -$56.1 million across 4 years, with a median of -$60.3 million in 2022.
  • Biggest five-year swings in Net Income: skyrocketed 71.64% in 2023 and later tumbled 508.27% in 2024.
  • Year by year, Net Income stood at -$61.2 million in 2022, then crashed by 61.09% to -$98.7 million in 2023, then increased by 24.06% to -$74.9 million in 2024, then surged by 61.78% to -$28.6 million in 2025.
  • Business Quant data shows Net Income for AXSM at -$28.6 million in Q4 2025, -$47.2 million in Q3 2025, and -$47.9 million in Q2 2025.